Polypoidal Choroidal Vasculopathy Clinical Trial
Official title:
OXiGENE OXC402-201: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Biological Effects of Intravenous Fosbretabulin in Asian Subjects With Polypoidal Choroidal Vasculopathy (PCV)
The primary objective of this study is to examine effects of fosbretabulin tromethamine (fosbretabulin) on PCV as reflected by a change from baseline in the number of polypoid lesions on indocyanine green angiography (ICGA).
Status | Completed |
Enrollment | 20 |
Est. completion date | August 2010 |
Est. primary completion date | August 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria - Male or female age =21 years. - Asian race (e.g. Chinese, Japanese, Korean, Thai). - Polypoidal choroidal vasculopathy in the study eye - Presence of = 1 visible polypoidal varicosity on ICGA. - Presence of a measurable branching vascular network - BCVA by ETDRS of 68 to 4 letters in the study eye. Ophthalmologic Exclusion Criteria - Prior treatment with intravitreal or systemic anti-VEGF therapy within 60 days of enrollment. - Any other prior treatment for PCV including thermal laser photocoagulation, photodynamic therapy (i.e., verteporfin), or any investigational therapies. - Any history of prior retinal or subretinal surgery, transpupillary thermography, radiation, implantation of intravitreal drug delivery device, vitrectomy. - Any other intraocular surgery or laser treatment within 90 days or any surgeries planned during the study period. - Fibrosis involving =50% of the total lesion. - Presence of hemorrhage which potentially obscures >75% of vascular pathology to be assessed by imaging procedures. - Retinal or choroidal vascular disease in study eye due to causes other than PCV, such as uveitis, trauma, or pathologic myopia. - Macular edema in either eye due to other causes, such as diabetic retinopathy. - Evidence of glaucomatous eye disease, glaucomatous visual field loss. - History of allergy to fluorescein or ICG dye. Medical Exclusion Criteria - Current or history within two years of any significant heart disease. - Uncontrolled hypertension. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Hong Kong | OXiGENE Investigational Site | Hong Kong | |
Korea, Republic of | OXiGENE Investigational Site | Seoul | |
Singapore | OXiGENE Investigational Site | Singapore | |
Taiwan | OXiGENE Investigational Site | Changhua | |
United States | OXiGENE Investigational Site | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
OXiGENE |
United States, Hong Kong, Korea, Republic of, Singapore, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate change in number of polypoid lesions on ICGA from baseline to Day 2 | from baseline to Day 2 | No | |
Primary | Evaluate change in the number of polypoid lesions on ICGA from baseline to Day 8 | from baseline to Day 8 | No | |
Secondary | Evaluate the change in area of the branching vascular network of PCV using ICGA from baseline to Day 2 | baseline to Day 2 | No | |
Secondary | Evaluate the change in the area of branching vascular network of PCV on ICGA from baseline to Day 8 | baseline to Day 8 | No | |
Secondary | Examine effects of fosbretabulin on choroidal neovasculariztion (CNV) and total lesion size using fluorescein angiography (FA) | Day 29 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT01950741 -
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Completed |
NCT01469156 -
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT02597855 -
Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography
|
N/A | |
Completed |
NCT02495181 -
Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Active, not recruiting |
NCT02976194 -
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Recruiting |
NCT01248117 -
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01884597 -
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04707027 -
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
|
N/A | |
Recruiting |
NCT02141308 -
OCT in Rare Chorioretinal Diseases
|
||
Completed |
NCT01871376 -
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
|
Phase 4 | |
Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT00383812 -
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
|
N/A | |
Completed |
NCT00837330 -
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
|
Phase 1/Phase 2 | |
Completed |
NCT05229237 -
Conbercept for Polypoidal Choroidal Vasculopathy(START Study)
|
||
Not yet recruiting |
NCT04380974 -
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Recruiting |
NCT02815176 -
Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers
|
N/A | |
Active, not recruiting |
NCT00344617 -
Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
|
Phase 3 | |
Recruiting |
NCT03929731 -
Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
|
||
Completed |
NCT02821520 -
Initial Versus Delayed PDT Combination With Conbercept in PCV
|
Phase 4 |